In An Inorganic Compound Patents (Class 424/1.61)
-
Publication number: 20130052131Abstract: Embodiments of the present disclosure, in one aspect, relate to a nanoparticle, methods of imaging a tumor, method of imaging a disease, method of treating a condition, disease, or related biological event, or the like.Type: ApplicationFiled: August 24, 2012Publication date: February 28, 2013Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Zhen Cheng, Kai Cheng
-
Publication number: 20130052129Abstract: The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty acid analogs are designed to enter the tissues of interest by the same long chain fatty acid carrier mechanism as natural fatty acids, however, functional substituents in the 2,3; 3,4; 4,5; 5,6 and other sequence positions, block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest.Type: ApplicationFiled: August 27, 2012Publication date: February 28, 2013Applicant: The General Hospital CorporationInventors: David R. Elmaleh, Alan J. Fischman, Timothy M. Shoup
-
Publication number: 20130022541Abstract: Disclosed herein are methods and compositions comprising fingolimod and anti-CD74 antibodies or fragments thereof. In preferred embodiments, the fingolimod increases the expression of CD74 in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 antibodies. The compositions and methods are of use to treat diseases involving CD74+ cells, such as cancer cells, autoimmune disease cells or immune dysfunction disease cells.Type: ApplicationFiled: July 18, 2012Publication date: January 24, 2013Applicants: IMMUNOMEDICS, INC., THE OHIO STATE UNIVERSITYInventors: Lapo Alinari, Robert A. Baiocchi, Natarajan Muthusamy, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20130004418Abstract: The invention relates to an infiltration solution of a radiopaque metal compound for treating an enamel lesion, to a kit for dental application, and to the use thereof for preventing and/or treating (sealing) carious enamel lesions.Type: ApplicationFiled: February 17, 2011Publication date: January 3, 2013Applicant: ERNST MUHLBAUER GMBH & CO. KGInventors: Swen Neander, Thomas Konig, Stephan Neffgen, Sebastian Paris, Hendrik Meyer-Luckel
-
Publication number: 20120315217Abstract: TSHR inverse agonists and neutral antagonists that are useful for treating Graves' orbitopathy, Graves' hyperthyroidism and/or thyroid cancer.Type: ApplicationFiled: April 8, 2011Publication date: December 13, 2012Inventors: Marvin Gershengorn, Susanne Neumann, Wenwei Huang, Craig J. Thomas
-
Patent number: 8317718Abstract: Methods for assessing an overall digestive health of a patient are provided, which include administering a breath test that uses a label incorporated into proteins, carbohydrates, and lipids and further incorporating the labeled material into a meal which, when cooked, facilitates the binding of the label material to the solid phase matrix of the meal. Methods for assessing digestive functions of a patient are also provided, which includes concurrently administering a breath test and a scintigraphy test that measure gastric emptying in a stomach.Type: GrantFiled: May 7, 2008Date of Patent: November 27, 2012Assignee: Advanced Breath Diagnostics, LLCInventors: Kerry C. Bush, Robert F. Martin
-
Publication number: 20120282179Abstract: Methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments are described, wherein R1 is halo; R2 is halo; and Q is CH or N.Type: ApplicationFiled: August 6, 2010Publication date: November 8, 2012Applicant: Exelixis, Inc.Inventors: Dana T. Aftab, Thomas Mueller, Aaron Weitzman, Jaymes Holland
-
Patent number: 8303931Abstract: The present invention pertains to a three compartment structured polymer nanoparticle (core-shell-corona) for multimodal imaging with specificity for cells or cellular components, thus enabling more advanced diagnostic approaches and targeted therapy on the cellular level without the use of additional biologically active materials.Type: GrantFiled: February 19, 2007Date of Patent: November 6, 2012Assignee: TOPASS GmbHInventors: Ulrich Pison, Bernd-Reiner Paulke, Silvia Pietschmann, Regis Cartier, Lutz Kaufner
-
Publication number: 20120276003Abstract: The present disclosure relates to a compound comprising an oxygen-15 and a process for preparation thereof. It also relates to the use of the compound in positron and/or other nuclide imaging and use of the compound in obtaining a perfusion and/or metabolic image in an animal and/or human body. A process for preparing the compound comprises irradiating a compound comprising oxygen via irradiation energy in the range of 10 MeV to 430 MeV. The oxygen atom in the compound may then be allowed to be converted to an oxygen-15 positron nuclide through a photonuclear reaction. Provided that the molecular structure of the irradiated compound is not disrupted, a compound comprising an oxygen-15 is prepared.Type: ApplicationFiled: September 25, 2011Publication date: November 1, 2012Applicant: Beijing Top Grade Medical Equipment Co., Ltd.Inventors: Jun Zeng, Qiyin Sun
-
Publication number: 20120276004Abstract: Provided herein are methods for determining the presence of cancer (malignant versus benign), monitoring the progression of cancer, monitoring cancer relapse, monitoring the response to cancer therapy, or cancer staging in a subject, by evaluating CD33+/HLA-DRlow, CD1430 /HLA-DRlow, CD66b+/HLA-DRlow or, CD11b+/HLA-DRlow MDSC for activation of a transcription factor. Transcription factors include, but are not limited to, STAT3, pSTAT3, HIF1?, or C/EBP?. The MDSC phenotype can be CD33+HLA-DRlowHIF1?+/STAT3+, CD14+HLA-DRlowHIF1?+/STAT3+/pSTAT3+/C/EBPb+, CD66b+HLA-DRlowHIF1?+/STAT3+/pSTAT3+/C/EBPb+, CD33+HLA-DRlowHIF1?+/STAT3+/pSTAT3+/C/EBPb+, CD11b+HLA-DRlow HIF1?+/STAT3+/pSTAT3+/C/EBPb+, or CD11b+HLA-DRlowC/EBP?+. Also provided herein are methods for inducing human MDSC from healthy donor peripheral blood mononuclear cells (PBMC) by co-culturing PBMC with human solid tumor cell lines and subsequently measuring their suppressive ability.Type: ApplicationFiled: April 27, 2012Publication date: November 1, 2012Inventors: Alan L. Epstein, Melissa G. Lechner
-
Patent number: 8293208Abstract: The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies.Type: GrantFiled: May 15, 2009Date of Patent: October 23, 2012Assignee: The Governors of the University of AlbertaInventors: Chris Cheeseman, Frederick West, Tina Grant, Brendan Trayner, John Mercer, Andrei Manolescu
-
Patent number: 8287839Abstract: The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity carborane-containing porphyrin compounds with halide, amine, or nitro groups and methods for their use particularly in boron neutron capture therapy (BNCT), X-ray radiation therapy (XRT), and photodynamic therapy (PDT) for the treatment of tumors of the brain, head and neck, and surrounding tissue. The invention is also directed to using these carborane-containing porphyrin compounds in methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET.Type: GrantFiled: December 4, 2006Date of Patent: October 16, 2012Assignee: Brookhaven Science Associates, LLCInventors: Michiko Miura, Mark W. Renner
-
Publication number: 20120251442Abstract: This invention provides a safer and more effective treatment for non-intracavitary undesirable tissue masses, especially bone cancer and soft tissue tumors. The method involves the direct administration of a therapeutically-effective dose of a formulated radioisotope composition nearby or directly into the tissue mass. Small volumes of the composition are used. Administration of the dose for bone cancer may be done through a hole or multiple holes created in the bone using a miniature drill. Delivery of the dose directly into a tumor may be accomplished using a microsyringe or a miniature pump capable of accurately delivering microliter amounts of material.Type: ApplicationFiled: May 11, 2012Publication date: October 4, 2012Applicants: GABRIEL INSTITUTE, INC., ISOTHERAPEUTICS GROUP LLCInventors: R. Keith Frank, Kenneth McMillan, Edna Sue McMillian, Jaime Simon, H. Max Loy, JR., Stanley D. Stearns
-
Patent number: 8277775Abstract: The present invention relates to FTY720 analogs bearing a boron dipyrromethene difluoro (BODIPY) fluorophore in the alkyl side chain and methods of preparation. The compounds of the present invention can be used in fluorescence spectroscopy and fluorescence microscopy and in chromatography using fluorescence detection.Type: GrantFiled: August 15, 2008Date of Patent: October 2, 2012Assignee: The Research Foundation of the City University of New YorkInventors: Robert Bittman, Zaiguo Li
-
Publication number: 20120232325Abstract: Methods are described for treating a target tissue with a radioisotope. Some methods include determining a distance between a target tissue and a surface of a matrix material to be positioned adjacent the target tissue and, based on the determined distance, determining an activity to be mixed with the matrix material to obtain a desired activity concentration. Some methods further include mixing the radioisotope with the matrix material. In some embodiments, the matrix material is a bone cement, and the target tissue is a tumor in a bone. The radioisotope may be a beta-emitting radioisotope mixed in the cement at a concentration to form a radioactive cement.Type: ApplicationFiled: February 23, 2012Publication date: September 13, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Joyce H. Keyak, Tadashi Kaneko, Harry B. Skinner, Varun Sehgal
-
Patent number: 8257681Abstract: Compositions of high specific activity 117mSn with specific activity of greater than 100 Ci/g Sn and methods of producing the same. The method includes exposing 116Cd to an ?-particle beam of sufficient incident kinetic energy and duration to convert a portion of the 116Cd to 117mSn to form an irradiated material. The irradiated material is dissolved to form an intermediate solution containing 117mSn and 116Cd. The 117mSn is separated from the 116Cd to yield high specific activity 117mSn.Type: GrantFiled: December 26, 2008Date of Patent: September 4, 2012Assignee: Clear Vascular Inc.Inventors: Nigel Raymond Stevenson, Ian Martin Horn
-
Publication number: 20120213700Abstract: The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce 99mTc-pertechnetate, Ascorbic Acid to reduce stannic ions to stannous ions to maintain a reducing environment, ?,?-Trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and Glycine to transchelate Technetium-99m under highly acidic conditions to facilitate radiolabeling DTPA-dextran with high radiochemical purity. In addition, the invention pertains to methods for making and using the compositions. The reconstitution of the lyophilized composition by 99mTc-pertechnetate, resulting in radiolabeled 99mTc-DTPA-dextran in a composition between pH 3 to 4.Type: ApplicationFiled: May 1, 2012Publication date: August 23, 2012Applicant: NAVIDEA BIOPHARMACEUTICALS, INC.Inventors: Gerald Ross Magneson, Richard Cushman Orahood
-
Patent number: 8246932Abstract: Composition of non-radioactive traceable metal isotope-enriched nanoparticles, and methods of their use for determining in-vivo biodistribution are provided. The methods comprise the steps of: (a) introducing the nanoparticles into the biological material, wherein the nanoparticles comprise at least one inorganic core, and the inorganic core comprises at least two metal isotopes in a predetermined ratio; wherein at least one metal isotope is enriched non-radioactive traceable metal isotope and (b) determining the distribution of the nanoparticles in the biological material based on the predetermined ratio of the metal isotopes.Type: GrantFiled: March 28, 2008Date of Patent: August 21, 2012Assignee: General Electric CompanyInventors: Peter John Bonitatibus, Jr., Amit Mohan Kulkarni, Andrew Soliz Torres, Ying Zhou, Chiaki Treynor, Daniel Eugene Meyer
-
Publication number: 20120164069Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.Type: ApplicationFiled: October 31, 2008Publication date: June 28, 2012Inventors: Edward S. Boyden, Daniel B. Cook, Roderick A. Hyde, Eric C. Leuthardt, Nathan P. Myhrvold, Elizabeth A. Sweeney, Lowell L. Wood, JR.
-
Publication number: 20120134921Abstract: This invention relates to solid compositions and solid pharmaceutical products for use in methods of photodynamic diagnosis of cancer, pre-cancerous and non-cancerous conditions in the lower part of the gastrointestinal system. The solid pharmaceutical compositions and pharmaceutical products comprise an active ingredient which is 5-aminolevulinic acid (5-ALA) or a precursor or derivative of 5-ALA or pharmaceutically acceptable salts thereof. The invention relates further to methods of photodynamic diagnosis of cancer, pre-cancerous and non-cancerous conditions of the lower gastrointestinal tract, wherein the solid pharmaceutical compositions and pharmaceutical products are used.Type: ApplicationFiled: June 11, 2010Publication date: May 31, 2012Applicant: Photocure ASAInventors: Oddveig Sellaeg Helland, Gry Stensrud, Bjorn Klem, Jon Erik Braenden, Aslak Godal, Jo Klavenes
-
Patent number: 8187638Abstract: Here we disclose the response of normal human cells to ZnO nanoparticles under different signaling environments and compare it to the response of cancerous cells. ZnO nanoparticles exhibit a strong preferential ability to kill cancerous T cells (˜28-35X) compared to normal cells. Interestingly, the activation state of the cell contributes toward nanoparticle toxicity as resting T cells display a relative resistance while cells stimulated through the T cell receptor and CD28 costimulatory pathway show greater toxicity in direct relation to the level of activation. The novel findings of cell selective toxicity towards potential disease causing cells indicate a potential utility of ZnO nanoparticle in the treatment of cancer and/or autoimmunity.Type: GrantFiled: September 22, 2008Date of Patent: May 29, 2012Assignee: Boise State UniversityInventors: Alex Punnoose, Madhusudan R. Kongara, Denise Wingett
-
Patent number: 8178315Abstract: A standardized, lyophilized edible food containing a biologically safe stable marker for use in the measurement of gastric emptying by the quantification of marker excreted in the breath of the patient.Type: GrantFiled: May 15, 2008Date of Patent: May 15, 2012Assignee: Advanced Breath Diagnostics, LLCInventors: Kerry C. Bush, Keith D. Evans, Stanley J. Konopka
-
Publication number: 20120095324Abstract: A method for a nuclear medicine examination of a patient is disclosed. In at least one embodiment of the method, a magnetic resonance recording of an examination region of the patient is created after a magnetic resonance contrast agent has been administered to the patient. A distribution of the magnetic resonance contrast agent in the examination region is automatically determined from the magnetic resonance recording. After a nuclear medicine tracer has been administered to the patient, a nuclear medicine recording of the examination region of the patient is created. The magnetic resonance contrast agent and the nuclear medicine tracer have essentially identical pharmacokinetic properties. The nuclear medicine recording is corrected as a function of the distribution of the magnetic resonance contrast agent in the examination region.Type: ApplicationFiled: October 13, 2011Publication date: April 19, 2012Applicant: SIEMENS AKTIENGESELLSCHAFTInventor: Sebastian Schmidt
-
Publication number: 20120082616Abstract: The present invention provides targeted delivery compositions and their methods of use in treating and diagnosing a disease state in a subject.Type: ApplicationFiled: September 23, 2011Publication date: April 5, 2012Applicant: Mallinckrodt LLCInventors: Bobby N. Trawick, Todd A. Osiek, James R. Wheatley, JR.
-
Patent number: 8147805Abstract: Compositions and methods for dual imaging and for dual chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns compounds comprising the structure X1—Y—X2, wherein Y comprises two or more carbohydrate residues covalently attached to one another, X1 and X2 are diagnostic or therapeutic moieties covalently attached to Y, provided that when Y does not comprise a glucosamine residue, X1 and X2 are diagnostic moieties. The present invention also concerns methods of synthesis of these compounds, application of such compounds for dual imaging and treatment of hyperproliferative disease, and kits for preparing a radiolabeled therapeutic or diagnostic compound.Type: GrantFiled: January 5, 2006Date of Patent: April 3, 2012Assignee: The Board of Regents of The University of T exas SystemInventors: David Yang, Dongfang Yu, Mithu Chanda, Ali Azhdarinia, Changsok Oh, E. Edmund Kim
-
Publication number: 20120076723Abstract: The invention relates to the treatment of cancer. In particular the invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive silicon, porous silicon, polycrystalline silicon, amorphous silicon, and bulk crystalline silicon, the internal therapeutic product being for the treatment of cancer.Type: ApplicationFiled: December 8, 2011Publication date: March 29, 2012Applicant: pSiMedica LimitedInventors: Roger ASTON, Leigh T. Canham
-
Publication number: 20120064002Abstract: Enantiomer-pure compounds of general formulas VIIa and VIIb in which A stands for a group —COO—, and Z and R have different meanings, as well as use thereof are described.Type: ApplicationFiled: March 31, 2011Publication date: March 15, 2012Inventors: Lutz LEHMANN, Matthias FRIEBE, Thomas BRUMBY, Detlev SUELZLE, Johannes PLATZEK
-
Publication number: 20120052008Abstract: Nanostructures comprising radioisotopes and/or metals are provided. More particularly, in some embodiments, nanostructures comprising radioisotopes and/or metals, methods of their synthesis, and their use in cancer imaging and therapy are provided.Type: ApplicationFiled: August 25, 2011Publication date: March 1, 2012Inventors: Yuri Mackeyev, Lon J. Wilson, Izabela Tworowska
-
Publication number: 20120027675Abstract: This invention provides novel compositions and methods for the specific and/or preferential delivery of an effector (e.g. a drug or label) to an epithelial cell (e.g. a pulmonary epithelium). The compositions comprise an adipocyte differentiation-related protein (ADRP) attached to an effector thereby forming a chimeric moiety. The chimeric moiety is preferentially delivered to epithelial cells.Type: ApplicationFiled: October 18, 2011Publication date: February 2, 2012Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: John S. Torday, Virender K. Rehan
-
Patent number: 8105635Abstract: The present invention relates to post-treatment compositions and methods useful for modifying the distribution of metal biocide(s) in biodegradable substrates such as wood, other cellulosic products, starch-based products, and the like that are vulnerable to decay due to insects, fungi, microbes, and the like. The compositions include complexing agents of moderate strength that are able to facilitate mobilization and redistribution of metal biocide(s) in substrates without undue leaching. The compositions can be used, for example, to redistribute the metal biocide(s) into depleted regions of a substrate by redistribution of metal biocide from other regions of the substrate. Post-treatment compositions that include additional metal biocide can also replenish these regions with the freshly supplied, additional biocide. Thus, the depleted regions can be restored by redistribution and/or replenishment mechanisms. Service life of substrates in the field benefits by these post-treatments as a consequence.Type: GrantFiled: March 12, 2009Date of Patent: January 31, 2012Assignee: Union Carbide Chemicals & Plastics Technology LLCInventors: Kimberly S. Hayson, William C. Hoffman, Albert F. Joseph, Brian T. Keen
-
Publication number: 20110318265Abstract: Provided are methods to treat cancer in which a patient is identified as having gallium-avid cancer by use of a gallium scan or other means, and is then treated with a pharmaceutically acceptable gallium composition.Type: ApplicationFiled: April 6, 2010Publication date: December 29, 2011Inventor: Lawrence R. Bernstein
-
Publication number: 20110301401Abstract: The present invention relates to compositions and methods for increasing tissue-radiosensitivity through induction of local hyperthermia. In particular, the present invention provides superparamagnetic, paramagnetic, or ferromagnetic radioactive particles that heat surrounding tissue upon magnetic induction, and methods of use thereof. In some embodiments, the present invention provides compositions and methods for thermoradiotherapy (e.g. anti-tumor therapy).Type: ApplicationFiled: June 8, 2011Publication date: December 8, 2011Inventors: Andrew C. Larson, Andrew C. Gordon, Reed A. Omary
-
Patent number: 8038999Abstract: A method of treating breast cancer that is at least partially ER+ is disclosed. The method comprises administering at a tumor site in a mammalian subject a pharmaceutically acceptable form of Fe(II) or Fe(III) in a suitable carrier. A four-part program aimed at eradicating breast cancer includes (a) local treatment and prevention of spread from a contained breast site, preferably using local administration of a ferric iron composition, (b) treatment of disseminated (metastatic) breast cancer, (c) reduction in the risk of developing breast cancer, preferably by enhancing dimeric/polymeric IgA and polymeric IgM inhibition of estrogen responsive cell growth, and (d) protection against cancer causing agents.Type: GrantFiled: November 28, 2007Date of Patent: October 18, 2011Inventor: David A. Sirbasku
-
Publication number: 20110229408Abstract: The present disclosure relates to a sodium iodide symporter (NIS)-repressor binding sites (NRBS) consensus sequence consisting of a DNA molecule having the sequence 5?-T/C(G/A)GCCT(T/C)A(G/A)TTTCCCCA(T/C)CTGT-3?(the “consensus NRBS”). The disclosure further relates to methods of restoring iodide transport in dedifferentiated thyroid cancer cells by interfering with formation or function of the NIS repressor.Type: ApplicationFiled: March 16, 2010Publication date: September 22, 2011Inventors: Kenneth AIN, Wei Li
-
Publication number: 20110150762Abstract: A bone cement configured to be introduced to a target bone location and allowed to cure includes at least a monomer, and an amount of bone marrow. The resulting cured bone cement includes at least one desired mechanical property that can be tailored to match a like mechanical property of the target bone. The mechanical property can be a material stiffness (Young's modulus) or yield strength.Type: ApplicationFiled: August 25, 2010Publication date: June 23, 2011Inventors: Andreas Boger, Daniel Arens, Markus Windolf, Armando Gisep
-
Publication number: 20110150763Abstract: The invention provides for Triazine derivatives and their use to modulate protein kinase activity in a variety of conditions and diseases.Type: ApplicationFiled: December 17, 2010Publication date: June 23, 2011Applicant: ABRAXIS BIOSCIENCE, LLCInventors: Chunlin Tao, Qinwei Wang, Neil P. Desai, Patrick Soon-Shiong
-
Publication number: 20110129417Abstract: The present invention relates to a composition suitable for administration to a subject, the composition comprising pharmacologically acceptable particulate material dispersed throughout a pharmacologically acceptable liquid carrier, the particulate material being maintained in the dispersed state by a steric stabiliser, wherein the steric stabiliser is a polymeric material comprising a steric stabilising polymeric segment and an anchoring polymeric segment, one or both of which are derived from one or more ethylenically unsaturated monomers that have been polymerised by a living polymerisation technique, wherein the steric stabilising polymeric segment is different from the anchoring polymeric segment, and wherein the anchoring polymeric segment has an affinity toward the surface of the particulate material and secures the stabiliser to the particulate material.Type: ApplicationFiled: May 15, 2009Publication date: June 2, 2011Applicant: University of SydneyInventors: Brian Stanley Hawkett, Nirmesh Jain, Thi Thuy Pham, Yanjun Wang, Gregory Goodman Warr
-
Publication number: 20110123445Abstract: The present invention provides a method for monitoring the effectiveness of atreatment, wherein said treatment comprises an inhibitor designed to treat a disease comprising abnormal activity of the Ras/Raf/MEK/ERK pathway.Type: ApplicationFiled: July 13, 2009Publication date: May 26, 2011Inventor: Pamela Cohen
-
Publication number: 20110104249Abstract: The subject invention concerns materials and methods for treating oncological disorders in a person or animal using any agent or compound that inhibits uptake of glucose into a cell. The subject invention also concerns methods for inducing apoptosis and inhibiting the proliferation or survival of a cell. In one embodiment, the methods comprise administering an effective amount of an agent or compound that inhibits the activity of one or more glucose transporter proteins, such as Glut-1. An antibody that binds to and inhibits a glucose transporter protein can be used in the present methods.Type: ApplicationFiled: August 15, 2008Publication date: May 5, 2011Applicant: University of South FloridaInventor: George R. Simon
-
Publication number: 20110064655Abstract: Differential expression of nucleic acids in the brains of subjects suffering from late-onset depression has been demonstrated. The invention provides methods useful in the determination of late-onset depression. Also provided by the present invention is a screening method for the identification of compounds for treatment, prevention or diagnosis of late-onset depression.Type: ApplicationFiled: May 15, 2009Publication date: March 17, 2011Inventors: Peter Hanson, Duncan Hiscock, Chris Morris, Alan Thomas
-
Publication number: 20110044897Abstract: The invention relates to a method for targeting an imaging agent to cells of an animal to detect localized infections. More particularly, localized infections are detected by targeting imaging agents to inflammatory cells having receptors for a vitamin by using vitamin-imaging agent conjugates.Type: ApplicationFiled: May 23, 2008Publication date: February 24, 2011Inventors: Philip Stewart Low, Walter Anthony Henne, JR., Bindu Varghese, Ryan Rothenbuhler
-
Publication number: 20110038792Abstract: Dual suppression of the MAP kinase and PI3K/Akt pathways showed synergistic or greatly enhanced anti-melanoma cell effects, compared to suppression of a single pathway, including the inhibition of cell proliferation, transformation and invasion, induction of G0/G1 cell cycle arrest and, importantly, cell apoptosis. Remarkably, suppression of either pathway induces the expression of thyroid iodide-handling genes and dual suppression of the two pathways synergistically and robustly induces expression of these genes, accompanied by uptake of radioiodine in the cells. These genes include sodium/iodide symporter, thyroid-stimulating hormone receptor, thyroglobulin, thyroperoxidase, pendrin gene, thyroid transcription factors (e.g., TTF-1, TTF-2, PAX8) and other thyroid genes.Type: ApplicationFiled: February 5, 2009Publication date: February 17, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventor: Michael Mingzhao Xing
-
Patent number: 7887782Abstract: The invention relates to novel radiotherapeutic formulations containing 224Ra and methods for their production. The invention discloses, in particular, radiotherapeutic formulations comprising at least one salt of the isotope 224Ra, which are characterized in that the content of other radionuclides, in particular, the respective content of certain longeval radionuclides does not exceed a specific numerical value in mBq/g. The invention also relates to a method for producing radiotherapeutic formulations of this type, which is characterized by the following steps: after at least one centrifugation of an aqueous suspension of the compound 228Th(OH)4 and optionally after the resuspension of the raw sediment obtained in said centrifugation, the precipitated 228Th(OH)4 sediment is separated. The supernatant solution of a 224Ra salt that has been obtained is subsequently subjected to sterile filtration and is then made up to the required dose.Type: GrantFiled: August 7, 2001Date of Patent: February 15, 2011Assignee: Altmann Therapie GmbH & Co.Inventors: Uwe Schwarz, Rolf Daniels
-
Publication number: 20100331676Abstract: The present invention relates to a method of detecting ?-amyloid peptide aggregates in the brain of an individual and kits thereto. The method includes administering to an individual an effective amount of an A?-binding radiopharmaceutical, waiting a period of time, measuring a gamma radiation count over an external area of the head corresponding to the cortex of the individual using a radiation detection device, and comparing the gamma radiation count with a control gamma radiation count.Type: ApplicationFiled: February 23, 2009Publication date: December 30, 2010Applicant: AVID RADIOPHARMACEUTICALS, INC.Inventor: Alan P. Carpenter
-
Publication number: 20100316565Abstract: The present invention relates to a method useful in facilitating the identification of fibrogenesis in a subject. The method of the invention is particularly useful when applied as part of a method to diagnose fibrogenesis of the liver. The invention also provides a compound for use in a method for identification of fibrogenesis in a subject A further aspect of the invention is a compound for use in the preparation of a medicament for use in a method for identification of fibrogenesis in a subject.Type: ApplicationFiled: November 19, 2008Publication date: December 16, 2010Inventors: Ben Newton, Salah Chettibi, Magne Solbakken
-
Publication number: 20100303719Abstract: The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation.Type: ApplicationFiled: January 12, 2009Publication date: December 2, 2010Applicant: NORTHWESTERN UNIVERSITYInventors: Sui Huang, John Norton, Daniel Appella, Mark Witschi
-
Publication number: 20100284912Abstract: A homogenous dispersion of aqueous droplets of a radiopharmaceutical or radiodiagnostic agent within a non-aqueous medium and method of making the same is provided. The homogenous dispersion is largely free of impurities and constitutes a substantially uniform distribution of sodium thiosulfate and radiopharmaceutical which is stable for a time sufficient to fill and solidify within gel capsules. In making the homogenous dispersion, dry sodium thiosulfate and dry potassium phosphate dibasic anhydrous are uniformly dispersed within non-aqueous, liquid polyethylene glycol.Type: ApplicationFiled: December 3, 2008Publication date: November 11, 2010Applicant: BRACCO DIAGNOSTICS INC.Inventors: Peter J. Oehlberg, Ernst Schramm
-
Publication number: 20100278729Abstract: A method of treating breast cancer that is at least partially ER+ is disclosed. The method comprises administering at a tumor site in a mammalian subject a pharmaceutically acceptable form of Fe(II) or Fe(III) in a suitable carrier. A four-part program aimed at eradicating breast cancer includes (a) local treatment and prevention of spread from a contained breast site, preferably using local administration of a ferric iron composition, (b) treatment of disseminated (metastatic) breast cancer, (c) reduction in the risk of developing breast cancer, preferably by enhancing dimeric/polymeric IgA and polymeric IgM inhibition of estrogen responsive cell growth, and (d) protection against cancer causing agents.Type: ApplicationFiled: November 28, 2007Publication date: November 4, 2010Applicant: Signe Biopharma Inc.Inventor: David Sirbasku
-
Publication number: 20100266493Abstract: The invention provides antibodies that bind the thyroid stimulating hormone receptor (TSHR), especially in humans, and their uses in diagnostic and therapeutic roles. The invention also provides hybridomas for producing such antibodies.Type: ApplicationFiled: March 29, 2007Publication date: October 21, 2010Applicant: KING'S COLLEGE LONDONInventors: Jasvinder-Paul Singh Banga, Jacqueline Ann Gilbert, Deborah Dunn-Walters
-
Publication number: 20100260670Abstract: This invention relates, e.g., to a method for determining if a thyroid tumor in a subject is malignant, comprising determining in a sample from the subject the amount of TERT (telomerase reverse transcriptase) mRNA which lacks the ? sequence and the amount of TERT mRNA in the sample which comprises the ? sequence, wherein a preponderance (e.g., at least about 55%) of TERT mRNA in the sample which comprises the ? sequence indicates that the tumor is malignant, and wherein a preponderance of TERT mRNA which lacks the ? sequence indicates that the tumor is not malignant.Type: ApplicationFiled: December 5, 2008Publication date: October 14, 2010Applicant: The Johns Hopkins UniversityInventors: Martha Allen Zeiger, Jeanne Kowalski, Christopher Umbricht, Yongchun Wang